163 related articles for article (PubMed ID: 28102361)
1. Effectiveness and Tolerability of Different Recommended Doses of PPIs and H
Zhang C; Kwong JS; Yuan RX; Chen H; Xu C; Wang YP; Yang GL; Yan JZ; Peng L; Zeng XT; Weng H; Luo J; Niu YM
Sci Rep; 2017 Jan; 7():41021. PubMed ID: 28102361
[TBL] [Abstract][Full Text] [Related]
2. Short-term treatment of gastroesophageal reflux disease.
van Pinxteren B; Numans ME; Lau J; de Wit NJ; Hungin AP; Bonis PA
J Gen Intern Med; 2003 Sep; 18(9):755-63. PubMed ID: 12950485
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of histamine-2 receptor antagonists as short-term therapy for gastro-esophageal reflux disease: a network meta-analysis.
Zhao F; Wang S; Liu L; Wang Y
Int J Clin Pharmacol Ther; 2016 Oct; 54(10):761-70. PubMed ID: 27443665
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and safety of proton pump inhibitors in infantile gastroesophageal reflux disease.
Higginbotham TW
Ann Pharmacother; 2010 Mar; 44(3):572-6. PubMed ID: 20124466
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of histamine-2 receptor antagonists.
van der Pol R; Langendam M; Benninga M; van Wijk M; Tabbers M
JAMA Pediatr; 2014 Oct; 168(10):947-54. PubMed ID: 25133940
[TBL] [Abstract][Full Text] [Related]
6. Vonoprazan versus proton pump inhibitors for the management of gastroesophageal reflux disease: A protocol for a systematic review with meta-analysis.
Kang H; Kim BJ; Choi G; Kim JG
Medicine (Baltimore); 2018 Sep; 97(39):e12574. PubMed ID: 30278564
[TBL] [Abstract][Full Text] [Related]
7. Observational cohort study: safety outcomes in children using proton pump inhibitors or histamine-2 receptor antagonists.
Houben E; Johansson S; Nagy P; Penning-van Beest FJA; Kuipers EJ; Herings RMC
Curr Med Res Opin; 2018 Apr; 34(4):577-583. PubMed ID: 29149805
[TBL] [Abstract][Full Text] [Related]
8. Drugs, bugs, and esophageal pH profiles.
Robinson M
Yale J Biol Med; 1999; 72(2-3):169-72. PubMed ID: 10780578
[TBL] [Abstract][Full Text] [Related]
9. New therapeutic options in the treatment of GERD and other acid-peptic disorders. Based on a presentation by Duane D. Webb, MD, FACG.
Am J Manag Care; 2000 May; 6(9 Suppl):S467-75. PubMed ID: 10977486
[TBL] [Abstract][Full Text] [Related]
10. Potential options to optimize therapy of gastroesophageal reflux disease with proton pump inhibitors.
Tonini M; Vigneri S; Neri M; Cuomo R; Savarino V; Pace F
Digestion; 2007; 76(3-4):171-8. PubMed ID: 18046084
[TBL] [Abstract][Full Text] [Related]
11. A critical evaluation of proton pump inhibitors in the treatment of gastroesophageal reflux disease.
Berardi RR
Am J Manag Care; 2000 May; 6(9 Suppl):S491-505. PubMed ID: 10977489
[TBL] [Abstract][Full Text] [Related]
12. A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease.
Gerson LB; Robbins AS; Garber A; Hornberger J; Triadafilopoulos G
Am J Gastroenterol; 2000 Feb; 95(2):395-407. PubMed ID: 10685741
[TBL] [Abstract][Full Text] [Related]
13. Limited ability of the proton-pump inhibitor test to identify patients with gastroesophageal reflux disease.
Bytzer P; Jones R; Vakil N; Junghard O; Lind T; Wernersson B; Dent J
Clin Gastroenterol Hepatol; 2012 Dec; 10(12):1360-6. PubMed ID: 22813439
[TBL] [Abstract][Full Text] [Related]
14. The Effect of H
Shim YK; Kim N
Korean J Gastroenterol; 2017 Jul; 70(1):4-12. PubMed ID: 28728310
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of once-daily esomeprazole for the treatment of gastroesophageal reflux disease in neonatal patients.
Davidson G; Wenzl TG; Thomson M; Omari T; Barker P; Lundborg P; Illueca M
J Pediatr; 2013 Sep; 163(3):692-8.e1-2. PubMed ID: 23800403
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of three different dosages of esomeprazole in the long-term management of reflux disease: a prospective, randomized study, using the wireless Bravo pH system.
Vasiliadis KV; Viazis N; Vlachogiannakos J; Sgouros SN; Stefanidis G; Archimandritis A; Karamanolis DG
Am J Gastroenterol; 2010 Feb; 105(2):308-13. PubMed ID: 19809412
[TBL] [Abstract][Full Text] [Related]
17. Phase I, multicenter, randomized, open-label study evaluating the pharmacokinetics and safety profile of repeated once-daily doses of intravenous esomeprazole in children 0 to 17 years of age.
Sandström M; Davidson G; Tolia V; Sullivan JE; Långström G; Lundborg P; Brown K
Clin Ther; 2012 Aug; 34(8):1828-38. PubMed ID: 22832034
[TBL] [Abstract][Full Text] [Related]
18. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis.
Chiba N; De Gara CJ; Wilkinson JM; Hunt RH
Gastroenterology; 1997 Jun; 112(6):1798-810. PubMed ID: 9178669
[TBL] [Abstract][Full Text] [Related]
19. Proton pump inhibitor prescribing and costs in a large outpatient clinic.
Hood W; McJunkin B; Warnock A; Girme A; Smith N; Robinson B
W V Med J; 2014; 110(1):16-21. PubMed ID: 24640269
[TBL] [Abstract][Full Text] [Related]
20. Maintenance treatment of mild gastroesophageal reflux disease with proton pump inhibitors taken on-demand: a meta-analysis.
Jiang YX; Chen Y; Kong X; Tong YL; Xu SC
Hepatogastroenterology; 2013; 60(125):1077-82. PubMed ID: 23803372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
